Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT03547973
Trial Phases:	Phase II	Protocol IDs:	IMMU-132-06 - TROPHY U-01 (primary) NCI-2018-03421
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Gilead
NCI Full Details:	http://clinicaltrials.gov/show/NCT03547973

Summary

The objective of this study is to evaluate the efficacy and safety of sacituzumab
govitecan-hziy monotherapy and with novel combinations in participants with metastatic
urothelial cancer (mUC).

Objectives

Non-Randomized for Cohorts 1,2,3, and 4; Randomized for Cohorts 5, 6, and 7. Cohort 5 has
been cancelled, effective December 2023.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.